February, 2020 – This issue brief discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.

In 2019, an estimated 5.5 million people in sub-Saharan Africa could be infected with difficult-to-treat subtypes of the hepatitis C virus (HCV). Our brief addresses why limited information exists on these subtypes and what steps countries can take to scale up diagnostic and treatment around these subtypes to keep in line with the World Health Organization (WHO)’s HCV elimination goals for 2030.